A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

Completed · Phase 1 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

This is a Phase 1 study, involving a 1-day dosing period, designed to test the safety of investigational study drug ARRY-403 in patients with Type 2 diabetes. Approximately 36 patients from the US will be enrolled in this study.

Key facts

Study ID

NCT00859755

Run by

Array BioPharma

People needed

41

Starts

2009-03-01

Last updated by the study team

2012-08-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Profil Institute for Clinical Research, Inc. — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.